Abstract Glutamine:fructose-6-phosphate amidotransferase (GFAT1) is the rate-limiting enzyme in the hexosamine biosynthetic pathway, which plays an important role in hyperglycemia-induced insulin resistance. To evaluate the role of GFAT1 expression, we analyzed the expression profiles of GFAT1 mRNA in various human tissues using reverse transcriptase-polymerase chain reaction. We report here the identification and cDNA cloning of a novel GFAT1 splice variant expressed abundantly in skeletal muscle and heart. This subtype, designated GFAT1-L, contains a 54-bp insertion within the GFAT1 coding sequence. Recombinant GFAT1-L protein possessed functional GFAT activities and biochemical characteristics similar to GFAT1. Previously, GFAT1 was considered a simplex enzyme. The identification of a novel GFAT1 subtype possessing functional enzymatic activity and tissue-specific expression should provide additional insight into the mechanism of skeletal muscle insulin resistance and diabetes complications.
Introduction
Insulin resistance, leading to chronic hyperglycemia, is a cardinal feature of noninsulin-dependent diabetes mellitus (NIDDM) (Rizza et al. 1981) . Recent studies have shown that increased activity of the hexosamine biosynthetic pathway might contribute to glucose-induced insulin resistance in skeletal muscle (DeFronzo et al. 1985; Garvey et al. 1987; Rossetti et al. 1990; Marshall et al. 1991; Baron et al. 1995; Robinson et al. 1995; Davidson et al. 1994; Virkamaki et al. 1997 ), which is a major organ of insulin resistance in NIDDM patients. Specifically, glutamine:fructose-6-phosphate amidotransferase (GFAT1), a key regulator and rate-limiting enzyme in the formation of hexosamine products (Crook et al. 1995; McClain et al. 1996; Daniels et al. 1996; Chen et al. 1997) , displays elevated activity in the skeletal muscle of NIDDM patients (Yki-Jarvinen et al. 1996) and in ob/ob mice, a rodent model of NIDDM . Transgenic mice overexpressing the GFAT1 gene in skeletal muscle and adipose tissue also exhibit insulin resistance, as determined by the hyperinsulinemic euglycemic glucose clump technique (Herbert et al. 1996; Cooksey et al. 1999) . On the other hand, in situ hybridization and immunostaining studies show that GFAT1 expression is normally tightly regulated in both a tissue-specific and a cell-specific manner (Nerlich et al. 1998; Yki-Jarvinen et al. 1999) . The recent identification of GFAT2, a highly similar gene that exhibits different tissue distribution from GFAT1, suggests additional levels of complexity in GFAT activity (Oki et al. 1999) .
Through examination of GFAT1 mRNA expression profiles, we have identified an additional GFAT1 variant expressed predominantly in skeletal muscle. We present here the cloning and biochemical characterization of a novel splice variant of GFAT1, designated GFAT1-L.
Materials and methods
Expression profile of GFAT1 mRNA Expression profile of GFAT1 mRNA was analyzed by polymerase chain reaction (PCR) amplification from commercially prepared human tissue cDNA libraries (QUICKClone human heart, brain, kidney, skeletal muscle, pancreas, liver, small intestine, and fat libraries; Clontech, Palo Alto, CA, USA) with GFAT1-specific primers (AGC CCTCTGTTGATTGGTGT and TCCATCTGGAGTGT TTGCAC). Amplification was performed using KOD dash polymerase (TOYOBO, Tokyo, Japan) under the following conditions: 40 cycles of 95°C for 30 s, 55°C for 30s, and 72°C for 45 s, with a final extension at 72°C for 1 min. PCR products were analyzed by electrophoresis through a 4% agarose gel.
Quantitative PCR analysis
Quantitative PCR analysis specific for the GFAT1-L gene was carried out using SYBR Green I methods (Wittwer et al. 1997; Morrison et al. 1998; Hiratsuka et al. 1999 ) and an ABI PRISM 7700 sequence detector (Perkin-Elmer Applied Biosystems, Foster City, CA, USA). Amplification mixes contained template DNA (described earlier), 10ϫ SYBR Green PCR buffer (Perkin-Elmer Applied Biosystems), 200 µM dNTPs, 5 mM MgCl 2 , 1.25 units of AmpliTaq Gold (Perkin-Elmer Applied Biosystems) and 5 pM of each primer (AGCTAGGACTCAGATTGGATC and TCCATCTGGAGTGTTTGCAC). The amplification was carried out for 50 cycles under the following conditions: 95°C for 30 s, 55°C for 30 s, and 72°C for 30 s. PCR products were quantified and normalized to human beta 2-microglobulin (beta 2-m) mRNA levels determined in parallel assays for each sample (GFAT1-L / beta 2-m). The ratios for mean expression levels ϮS.D. in each tissue relative to skeletal muscle were shown. Assays were performed in duplicate and repeated four times.
Cloning of full-length GFAT1-L cDNA A full-length GFAT1-L cDNA was PCR-amplified from human skeletal muscle QUICK-Clone cDNA (Clontech) using the primers TTTTTTTCATATGTGTGGTATATT TGCTTACTTAAACTAC and CCCTCGAGTTACTCT ACAGTCACAGATTTGGC. Reactions were carried out for 40 cycles under the following conditions: 95°C for 30 s, 55°C for 30 s, and 72°C for 2 min, with a final extension at 72°C for 3 min. The PCR product was isolated by 0.8% agarose gel electrophoresis, purified, inserted into the pT7Blue T-vector (Novagen, Madison, WI, USA), and sequenced.
Construction of Escherichia coli expression vectors for GFAT1 and GFAT1-L cDNAs
To increase expression levels of GFAT1 and GFAT1-L proteins in E. coli, we used PCR-based mutagenesis to introduce conservative mutations, converting E. coli lowusage codons to high-usage codons within the human GFAT1 and GFAT1-L gene sequences. Reverse transcription was performed using 2µg of human skeletal muscle mRNA, the primer P4 (CCCTCGAGTTACTCTACAGT CACAGATTTGGC), and M-MLV reverse transcriptase (Gibco BRL, Grand Island, NY) for 10min at 37°C followed by a 5-min denaturation step. We performed PCR using the mutagenesis primer P1 GTTCCGCGTACTCGT CGTGAAATCCTGGAGACC (underlined nucleotides denote substitutions in the GFAT1 sequence), primer P4, and KOD dash polymerase (TOYOBO). The amplification was executed under the following conditions: preheated at 95°C for 1min, 40 cycles at 95°C for 30 s, 55°C for 30 s, and 72°C for 45 s, with a final extension at 72°C for 1min. A second PCR reaction was performed using 5 µl of the above PCR product as template, the mutagenesis primer P2 GCTTACCTGAACTACCACGTTCCGCGTACTCGT, and primer P4 under the same conditions. Five microliters of the second PCR product was reamplified using the mutagenesis primer P3 TTTTTTTCATATGTGTGGTATCT TTGCTTACCTGAACTAC and primer P4 under the same conditions. The final PCR product was analyzed by 0.8% agarose gel electrophoresis, purified, inserted into the pET23b vector (Novagen), and sequenced.
Expression and purification of recombinant GFAT1 and GFAT1-L Vectors containing the full-length GFAT1 and GFAT1-L coding sequences, pET23/GFAT1 and pET23/GFAT1-L, were transformed into the E. coli strain BL21-Codon Plus (DE3)-RIL (Stratagene, La Jolla, CA, USA). Cultures were grown in Luria-Bertani medium containing 50mg/l ampicillin at 30°C overnight. Fifty microliters of the culture was added to 1l of the fresh medium and incubated for 3 h at 37°C with vigorous agitation. Following the addition of 2ml of 1 M isopropyl--D-thiogalactopyranoside (Wako Pure Chemicals Industries, Tokyo, Japan), cultures were incubated for 18 h at 20°C with vigorous agitation. Cells were harvested from 1l of culture by centrifugation, and the bacteria pellet was washed with cold Dulbecco's PBS (Ϫ) (Nissui Pharmaceutical, Tokyo, Japan). The cell pellet was the suspended in sonication buffer (50 mM sodium phosphate buffer [pH7.5] containing 20% [v/v] glycerol). After sonication, the lysate was centrifuged at 100,000g for 30 min at 4°C.
To concentrate the recombinant GFAT1 and GFAT1-L proteins, we slowly added 100% saturated ammonium sulfate solution to the lysates to obtain 55% saturation. After centrifugation at 15,000rpm for 30 min, the precipitates were dissolved in buffer G (50mM sodium phosphate buffer [pH7.5] containing 20% [v/v] glycerol and 1mM dithiothreitol) and desalted using a PD-10 gel filtration column (Amersham Pharmacia Biotech, UK). The concentrated sample solution was applied to a DEAESepharose column, which had been preequilibrated with buffer G. The sample was eluted with buffer G containing 0.1 M NaCl. Fractions containing recombinant GFAT1 were applied to a Sulfate-Cellulofine column that had been preequilibrated with buffer G containing 0.1 M NaCl. Proteins were step eluted with buffer G containing 0.1 M, 0.2 M, 0.3 M, 0.4 M, and 0.5 M NaCl. Fractions containing recombinant GFAT1-L were applied to a Heparin-Sepharose CL-6B column that had been preequilibrated with buffer G containing 0.1 M NaCl. Proteins were step eluted with buffer G containing 0.1 M, 0.2M, and 0.3 M NaCl.
The sample was mixed with sodiumdodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (62.5 mM Assays of enzyme activity GFAT activities were measured using a spectrophotometric assay, as described in Marshall et al. (1991) . In a typical assay, 200 µl of substrate buffer (400 mM sodium phosphate buffer [pH7.5], 50mM KCl, 1.25 mM ethylenediaminetetraacetate, 0.3 mM 3-acetylpyridine adenine dinucleotide [APAD], 6 U/ml glutamate dehydrogenase, 0-6mM fructose-6-phosphate [F6P]) was incubated with 50 µl of diluted human GFAT1 or GFAT1-L recombinant protein for 60 min at 37°C. The change in absorbance due to reduction of APAD to APADH was monitored spectrophotometrically at 365 nm.
Results and discussion

Expression profiles of GFAT1
To investigate the role of GFAT1 gene expression in insulin resistance, we examined expression profiles in human-tissue cDNA panels (Fig. 1) . In the skeletal muscle cDNA library, we observed two distinct PCR products of 323 bp and 377 bp. Sequence analysis identified the smaller product as the previously reported GFAT1 cDNA sequence (McKnight et al. 1992) , whereas the larger product contained a novel 54-bp insertion between nucleotides 685 and 686 of the GFAT1 cDNA. We have designated this variant GFAT1-L. PCR products corresponding to GFAT1-L were detected in skeletal muscle and heart, with weak expression observed in brain. On the other hand, PCR products corresponding to GFAT1 were detected uniformly in all tissues.
To measure the relative levels of GFAT1-L mRNA in various tissue types, we performed quantitative PCR analysis (Fig. 2) . Data were normalized to human beta 2-microglobulin mRNA levels. The highest levels of GFAT1-L expression were seen in skeletal muscle and heart, whereas low levels of expression were seen in brain. GFAT1-L expression in skeletal muscle was about 1.4 times higher than in heart and about 3.2 times higher than in brain. In other tissues, only background levels of expression were observed. These findings suggest that expression of GFAT1-L is regulated in a tissue-specific manner.
Recently, the GFAT2 gene, which shares high homology with GFAT1, was isolated (Oki et al. 1999) . Northern blot analysis showed differences in tissue distribution between GFAT1 and GFAT2. The highest levels of GFAT2 gene expression were observed in heart, placenta, and throughout the central nervous system. In contrast, GFAT1-L is expressed most abundantly in skeletal muscle, the most important tissue of insulin resistance in NIDDM (Rossetti et al. 1990; DeFronzo et al. 1985) . In light of the known role of GFAT1 activation in insulin resistance, it is possible that GFAT1-L is also involved in the mechanism of skeletal muscle insulin resistance.
Cloning of a novel GFAT1 splice variant
To confirm the presence of complete transcripts coding for the putative GFAT1-L open reading frame, we isolated a Fig. 1 . Detection of two alternative splice transcripts, human GFAT1 and GFAT1-L, by reverse transcriptase-polymerase chain reaction (RT-PCR). PCR was performed using QUICK-clone cDNA panels as templates. GFAT1-L transcripts were identified in human heart, brain, and skeletal muscle Fig. 2 . Quantitative analysis of GFAT1-L mRNA in tissues. SYBR Green I quantitative PCR methods were performed in duplicate and repeated four times. Levels of GFAT1-L mRNA amplification were normalized by comparison with human beta 2-microglobulin mRNA. Results show the mean ϮS.D. expression levels relative to skeletal muscle full-length cDNA clone from the human skeletal muscle cDNA library. DNA and amino acid sequences of GFAT1 and GFAT1-L, along with schematic representations of GFAT1 and GFAT-1L proteins, are presented in Fig. 3a,b . Aside from the insertion, the sequences of GFAT1 and GFAT1-L were identical. The GFAT1-L open reading frame consists of 2097 nucleotides, encoding a 699-aminoacid protein with a predicted molecular mass of 78790.38 Da (GFAT1: 2043 bp, 681 amino acids, and 76743.22 Da). The GFAT1-L insertion occurs within a sequence corresponding to a hinge region in the GFAT1 protein (Zhou et al. 1998 ).
Expression of GFAT1 and GFAT1-L protein and GFAT activity assay
To produce recombinant GFAT1 and GFAT1-L proteins, we subcloned full-length cDNAs for these variants into E. coli expression vector pET23 vector and introduced them into E. coli strain BL21-Codon Plus (DE3)-RIL. As shown in Fig. 4 , the approximately 77-and 79-kDa proteins were purified GFAT1 and GFAT1-L, respectively, which Fig. 3.a,b Comparison of human GFAT1 and GFAT1-L sequences. a Schematic diagram of GFAT1 and GFAT1-L showing the GFAT1-L 54-bp insertion sequence. b Nucleotide and amino acid sequences of the hinge regions of human GFAT1 and GFAT1-L. Amino acid sequences of GFAT1 and GFAT1-L are indicated below and above the nucleotide sequences, respectively. Asterisks indicate nucleotide identity between GFAT1 and GFAT1-L. A putative protein kinase A phosphorylation site is boxed Fig. 4 . Expression of recombinant GFAT1 and GFAT1-L proteins. Lane 1, molecular weight standards; lane 2, GFAT1; lane 3, GFAT1-L. Proteins were solubilized in the sample buffer, and proteins were fractionated on a 13% sodium dodecyl sulfate polyacrylamide gel and stained with Coomassie Brilliant Blue R-250. Arrow at right denote recombinant GFAT1 and GFAT1-L proteins is in reasonable agreement with the molecular masses predicted.
To determine if the GFAT1-L protein being expressed was functional, GFAT enzymatic activities were measured (Fig. 5) . As can be seen in Fig. 5 , GFAT enzymatic activities were shown in recombinant GFAT1-L proteins to be the same as recombinant GFAT1 proteins. The Km values of GFAT1 and GFAT1-L were derived from LineweaverBurk plots of activities using F6P as a substrate (Fig. 5) .
The Km values of GFAT1 and GFAT1-L for F6P were calculated to be 1.02 mM and 1.38 mM respectively. Vmax values of GFAT1 and GFAT1-L for F6P were calculated to be 1.92 µmol/min/mg and 1.02 µmol/min/mg, respectively. Some differences were shown in kinetic data between GFAT1 and GFAT1-L. The Vmax value showed two fold differences. Further investigation will be needed to understand whether these differences are significant in biochemical function.
We have described the identification of GFAT1-L, a novel splice variant of human GFAT1. GFAT1-L contains a 54-bp insertion in the GFAT1 open reading frame, corresponding to an 18-amino-acid insertion in the predicted hinge region of the GFAT1 protein. Moreover, recombinant GFAT1-L proteins display functional GFAT enzymatic activities in vitro. These findings strongly suggest the existence of a functional variant of GFAT1 in vivo, previously considered to be a simplex enzyme. Also, the unique tissue distribution makes GFAT1-L a very interesting target for further research on the tissue-specific regulation of hexosamine generation and the potential link to insulin resistance. Zhou et al. (1998) have shown that GFAT1 activity is regulated through phosphorylation by cAMP-dependent protein kinase A (PKA). Human GFAT1 contains two potential PKA phosphorylation sites. Using mass spectroscopy, Chang et al. (2000) recently mapped the PKA phosphorylation sites, demonstrating that GFAT1 is stoichiometrically phosphorylated at serine 205 and phospho- . GFAT enzyme activities were assayed at varying concentrations of fructose-6-phosphate. The reaction velocity was monitored spectrophotometrically (A 365 ). The dependence of the initial reaction velocity on substrate concentration was plotted in a linear fashion (Lineweaver-Burk plots). Each data point represents the mean of duplicate samples rylated to a lesser extent at serine 235. This region, called the GFAT hinge region, is thought to be the regulatory element for GFAT activity. It is likely that the 18-aminoacid insertion into this hinge region in GFAT1-L results in altered substrate binding or phosphorylation. Further investigation is required to confirm the potential effects of this insertion on substrate binding or phosphorylation in vitro and in vivo.
It will be interesting to compare the contributions of GFAT1-L to skeletal muscle insulin resistance with the contributions of GFAT1, as defined by the studies of GFAT1 transgenic mice (Hebert et al. 1996; Cooksey et al. 1999) and GFAT1 overexpression in fibroblast cells (Crook et al. 1995 , Crook et al. 2000 . Also, immunostaining and in situ hybridization studies of GFAT should be revisited, as it will be possible to distinguish between GFAT1, GFAT1-L, and GFAT2. The identification of GFAT1-L has the potential to open new avenues of research into the mechanism of insulin resistance.
